©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96267
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96267
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96267
Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma
Fei-Da Wu, Hai-Feng Zhou, Wei Yang, Di Zhu, Bi-Fei Wu, Hai-Bin Shi, Sheng Liu, Wei-Zhong Zhou, Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Co-first authors: Fei-Da Wu and Hai-Feng Zhou.
Co-corresponding authors: Sheng Liu and Wei-Zhong Zhou.
Author contributions: Wu FD and Zhou HF contributed equally to this article, they are the co-first authors of this manuscript. Wu FD analyzed the data and wrote the manuscript; Wu FD, Zhou HF, and Zhou WZ designed the research study; Wu FD, Zhu D, Yang W, and Wu BF performed the research; Shi HB, Liu S, and Zhou WZ provided financial support; Liu S and Zhou WZ made equally important contributions to the design, implementation and writing of this study, they are the co-corresponding authors of this manuscript; and all authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the First Affiliated Hospital of Nanjing Medical University Institutional Review Board, approval No. 2023-SR-902.
Informed consent statement: The study was a retrospective study and therefore no informed consent was obtained from the participants.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at xmjbq007@163.com.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Corresponding author: Wei-Zhong Zhou, MD, PhD, Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing 210029, Jiangsu Province, China. xmjbq007@163.com
Received: May 1, 2024
Revised: October 16, 2024
Accepted: November 5, 2024
Published online: January 15, 2025
Processing time: 225 Days and 5.2 Hours
Revised: October 16, 2024
Accepted: November 5, 2024
Published online: January 15, 2025
Processing time: 225 Days and 5.2 Hours
Core Tip
Core Tip: This study evaluates the efficacy and safety of combining transarterial chemoembolization (TACE) with lenvatinib and sintilimab compared to TACE with lenvatinib alone in patients with intermediate-advanced hepatocellular carcinoma. The results indicate that TACE with lenvatinib and sintilimab significantly improves overall survival (22.4 months vs 14.1 months) and progression-free survival (14.1 months vs 9.6 months), with a higher objective response rate (70% vs 55.6%). Notably, no severe adverse events were reported, suggesting that the combination therapy is effective and safe. These findings support the inclusion of sintilimab in hepatocellular carcinoma treatment regimens.